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EDITORIAL REVIEW
Pathogenesis and approaches to therapy of
membranoproliferative glomerulonephritis
In 1965, it was observed that patients with glomer-
ulonephritis with persistently low serum concentra-
tions of C3 evolved to have similar glomerular mor-
phologic characteristics, particularly recognizable in
biopsy specimens stained by the Jones methenamine
silver technique [1]. Subsequent observations have
indicated that although long-standing hypocomple-
mentemia is commonly observed and is unique in
patients with these glomerular morphologic charac-
teristics, reduced C3 concentrations are not always
present [2, 3] and the distinctive morphology is now
the criterion for identification of the disease. Thus,
the name first given, hypocomplementemic persistent
(chronic) glomerulonephritis [1], is no longer appro-
priate and the descriptive terms membranoprolifera-
tive and mesangiocapillary glomerulonephritis have
subsequently been applied.
With time, electron microscopy of the glomerular
lesion has shown that, based on the location of the
glomerular deposits, patients with membranoprolif-
erative morphologic characteristics fall into two
groups. In about two-thirds of the patients [4], the
deposits are present in the mesangium and in the
subendothelial space. The basement membrane is nor-
mal. This form has been designated type I membrano-
proliferative glomerulonephritis (MPGN). In the re-
mainder of the patients, deposits are present within
the glomerular basement membrane as well as within
the mesangium; subendothelial deposits are scanty or
absent. This form, designated type II MPGN, or in-
tramembranous dense deposit disease, was first recog-
nized independently in 1963 [5]. In this form, dense
deposits are also found in the basement membranes
of Bowman's capsule and of the tubules. In addition,
lobular glomerulonephritis is now recognized as a
form of MPGN [4, 6, 7]. It should be noted that
glomerular morphology closely resembling that of
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type I MPGN may occasionally be seen in the ne-
phritis accompanying chronic bacteremia, systemic
lupus erythematosus and anaphylactoid purpura [4,
8].
The two types of MPGN have similar clinical mani-
festations but in clinical course they differ in that, as a
group, crescents are more often present in type II and
survival is shorter [4, 9]. They also differ immunolog-
ically. In type I, the serum complement profile is
often indicative of classical pathway activation and
immunohistologic study always indicates glomerular
deposits of C3 and properdin and, in many cases,
significant amounts of immunoglobulin, Clq and C4
[4, 9, 10, 11]. In type lIthe complement profile is
suggestive of alternative pathway activation and a
complement-reactive factor, the C3 nephritic factor,
is more often demonstrable in the serum than in
patients with type I disease [9, 10, 11]. By immu-
nofluorescence, C3 is abundant in the glomeruli but
immunoglobulins, early reacting components of com-
plement and properdin are either absent or present in
only small amounts [4,9, 10, 11].
In this paper, details of the glomerular morphology
in MPGN are reviewed as a setting for a review of
current concepts of etiology and pathogenesis. In the
light of these observations, possible approaches to
therapy are discussed.
Glomerular morphology
All forms of the disease have in common marked
hyperplasia of the mesangium. A characteristic of
type I disease is the presence of mesangial inter-
position, consisting of extensions of mesangial cells,
or of whole mesangial cells, into the subendothelial
space. This together with the mesangial hyperplasia
greatly compromises capillary lumens and is respon-
sible for the interpretation of early workers that the
basement membrane, as viewed in PAS- and silver-
stained preparations, was split ("double contoured"
or "tram-track" appearance). By electron micros-
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copy, however, the true basement membrane ap-
pears largely intact.
In type 11 disease, the mesangial hyperplasia may
be less severe, capillary lumens less compromised and
the glomeruli less frequently enlarged [4, 10, 12].
Mesangial interposition and the double contoured
appearance may be present only in a patchy distribu-
tion [4, 10, 12] and the capillary walls are thickened
by the hallmark of the disease, the deposition of elec-
tron dense material within the glomerular basement
membrane. Hump-like subepithelial deposits are of-
ten present and may be numerous [9].
In the lobular form of the disease, the markedly
accentuated lobulation of the glomerulus is due to
profound mesangial hyperplasia, increase in mesan-
gial matrix and to the presence of centrolobular scle-
rotic nodules, the hallmark of this variant. Capillary
lumens, confined to the periphery of the enlarged
lobules, are greatly reduced in diameter [6]. The de-
posits may be those characteristic of either type I or
type II disease [10].
The correlation between glomerular morphologic
characteristics and function is poor [4, 13]. The gb-
merular filtration rate may be normal even when
open capillary lumens are infrequent and capillary
walls are greatly thickened by mesangial interposition
or dense deposits.
A characteristic of the disease which has a bearing
on therapeutic trials is the infrequency with which
spontaneous improvement in glomerular mor-
phology is observed. Although proliferation and
lobularity may tend to diminish in severity with time
[10, 14], it is unusual to observe significant changes in
morphologic characteristics [4] even though the dis-
ease may go into a complete remission with respect to
clinical manifestations. Occasionally, mesangial inter-
position and the dense intramenbranous deposits
may regress [10]. One patient in each of two series of
cases showed spontaneous improvement in glomeru-
lar morphologic characteristics [15, 16] and in one of
these the improvement was not striking [15].
Etiology
The cause of the disease is not known. The onset is
often without symptoms and not observed by the
physician. In some patients, the diagnosis follows the
chance discovery of proteinuria and microhematuria
[14] and in others, old medical records have revealed
that proteinuria and hematuria antedated symptoms
by a long period (nine years in one case) [1, 15]. A
"silent" onset is said to be more common in type I
disease [9].
The fact that a number of patients at presentation
have an acute nephritic syndrome and marked gb-
merular proliferation and exudation [1, 14, 17] raises
the question of whether the disease represents a Se-
quella of acute poststreptococcal glomerulonephritis.
The apparent onset occasionally follows a streptococ-
cal infection. This sequence is observed more often in
type II than in type I disease [9, 10]. In type II dis-
ease, numerous subepithelial deposits resembling
"humps" may be present [9, 17]. In those with a
symptomless onset, one might postulate a subclinical
acute poststreptococcal glomerubonephritis as the ini-
tiating event. There is, however, no firm evidence for
this origin.
The disease has been seen in siblings [16, 18] and a
predisposition to it may be inherited or, conceivably,
it might be the result of an infectious agent. In one of
thesereports, both siblings had type I MPGN [16].
Of great interest is the observation that type II
MPGN occurs with high frequency in patients with
partial lipodystrophy [19-21]. Such patients are fre-
quently hypocomplementemic and a complement-re-
active factor, presumably the C3 nephritic factor, is
demonstrable in their serum [19, 22]. Further study
of the lipodystrophic patients has shown that they fall
into three groups, those with neither hypocomple-
mentemia and nephritis, those with hypocomplemen-
temia only and those with both hypocomplemen-
temia and nephritis [23]. It would appear that
hypocomplementemia develops first, followed by the
nephritis.
Based in part on these observations, Peters and
Williams [23] have postulated that a deficiency of a
complement component may result in immune com-
plex disease by predisposing the patient to recurrent
or chronic infection. Since ability to form antibody is
unimpaired, circulating immune complexes become
abundant. An unusual number of patients with com-
plement deficiency have developed some form of
gbomerubonephritis. Gbomerulonephritis has been ob-
served in patients with Clr deficiency [24], with hered-
itary angioedema (low concentrations of C2 and C4)
[19, 24] and with C2 deficiency [24, 25]. On the other
hand, complement deficiency appears to predispose
to recurrent or chronic infection only in patients with
deficiency centering about C3 and CS but none of
these have had nephritis [26-28]. C2 deficiency, for
example, may be associated with no abnormality
[29], or symptoms of systemic lupus erythematosus
may be present but the syndrome is noteworthy for
the absence of glomerulonephritis [23]. Only two
patients with C2 deficiency have had recurrenl [30] or
chronic [31] infection but neither had evidence of
renal disease.
With one exception [22], patients with partial lip-
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odystrophy have not been noted to be subject to re-
current or chronic infection [21, 32]. To explain the
association of MPGN with partial lipodystrophy, it
would be equally attractive to postulate that the event
initiating the lipodystrophy is a viral infection and
that persistent shedding of virus, perhaps in com-
bination with an abnormal immune response, as pos-
tulated by Peters and Lachmann [33], leads to genesis
of nephritic factor and of nephritogenic complexes
which uniquely produce type II MPGN.
Pathogenesis
Role of glomerular deposits in pathogenesis. In type
I MPGN, the glomerular deposition of material ca-
pable of activating the classical complement pathway
appears to be responsible for the glomerular in-
flammatory reaction. Immunofluorescence studies
have usually shown, in addition to C3, the presence
of Clq, C4, properdin and immunoglobulins in the
glomerular deposits [4, 9, 10]. It has been suggested
that the occasional patient with type I disease without
deposits containing immunoglobulins, properdin and
early reacting components has a different disease [9,
10]. However, it seems equally possible that the de-
terminants of immunoglobulin and early reacting
components may become undetectable because of ex-
tensive deposition of C3 or because the material com-
posing the deposits is intermittently present in the
circulation and, in its absence, degradation of de-
terminants of previously deposited material occurs.
In serial biopsies, lgG has been detectable in some
specimens but not in others [8]. Evidence that the
material comprising the deposits activates the clas-
sical pathway while in the circulation is provided by
the complement profile as will be described in the
following.
The glomerular morphology in type I MPGN
would suggest that the material deposited in the
glomeruli cannot penetrate the glomerular basement
membrane. Since the studies of Farquhar and Palade
[34], it has been known that particles which cannot
penetrate the glomerular basement membrane ac-
cumulate in the mesangium. They showed that such
particles accumulate first in the subendothelial space
and then, apparently by movement in the sub-
endothelial space, reach the axial portion of the cap-
illary where they enter the mesangium. In chronic
serum sickness produced in rabbits by daily injections
of bovine serum albumin (BSA), it was noted [16]
that animals which produce intermediate amounts of
antibody to BSA form relatively large circulating
complexes which deposit exclusively in the mesan-
gium. In these animals, however, the complete mor-
phologic picture of MPGN was not produced. The
only experimental disease resembling MPGN is the
nephritis which accompanies trypanosomiasis in
monkeys [35].
Assuming glomerular morphology is dependent on
complex penetrability, disease resembling type I
MPGN would be expected to occur in other human
nephritides if impenetrable nephritogenic complexes
were present. The development of this glomerular
morphology in occasional cases of lupus and anaphy-
lactoid nephritis and of the nephritis of chronic bacte-
remia [4, 8] is thus understandable.
In type II MPGN, the nature of the complexes and
their role in pathogenesis is not clear. In this form,
the deposits present in the mesangium and in the
basement membranes fluoresce only with labeled anti-
body to C3 [9, 10]. Immunoglobulins are usually ab-
sent or present in scanty amounts in the mesangium
and early reacting complement components and pro-
perdin are not detectable. The fact that dense depos-
its containing C3 are found not only in the glomeru-
lar basement membrane but also in the basement
membranes of Bowman's capsule and of the tubules
[4, 5, 7, 9, 10] makes it difficult to explain the disease
as the result of deposition of complexes which can
partially penetrate the glomerular basement mem-
brane. Also difficult to explain is the poor survival
rate of patients with type II disease. The deposits in
the glomerular basement membrane appear to be rela-
tively benign; they persist even though other aspects
of glomerular morphology and the clinical status of
the patient improve with therapy [12] and may be
abundant in transplanted kidneys which show other-
wise little morphologic or clinical evidence of glome-
rulonephritis [36]. Deposits, other than in the base-
ment membrane, are often less abundant than in type
I and, presumably as a consequence, mesangial pro-
liferation is often less severe [4, 10, 12]. Thus, it is
difficult to understand the greater predisposition of
patients with type II disease to develop crescents and
to have rapid deterioration of function [9].
The pathogenesis of the lobular form of the disease
is also not clear; conceivably this form represents an
altered host response.
Role of complement in pat hogenesis. Although early
studies of complement in MPGN gave evidence that
the hypocomplementemia was produced by alterna-
tive pathway activation and thus differed from other
hypocomplementemic nephritides, recent observa-
tions have required revision of this concept. Early
studies focused on the role of the C3 nephritic factor
as causative of the hypocomplementemia. Activity of
this factor in producing C3 conversion was demon-
strable in the absence of early reacting complement
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components [37] and was found to be dependent on
the presence of factor B and other components of the
alternative pathway [38, 39]. It is now known, how-
ever, that complement concentrations in the two
forms of MPGN differ. In type I disease, the hypo-
complementemia, as assessed by C3 concentrations,
is often not marked and varies considerably with time
[10]. In type II disease, markedly depressed C3 con-
centrations are frequently observed and the levels of-
ten remain low over long periods [9, 10].
Measurements of other complement components
have given evidence that in type I disease, classical
pathway activation is occurring. Clq [11] and C4 [10,
11] concentrations may be reduced whereas low levels
of these components are less frequently observed in
type II disease [9-11] and C3NeF activity is more
often demonstrable in the serum [11]. In both types,
CS concentrations may be low in parallel with the
reduction in C3 [11].
Whereas the nephritic factor appears primarily re-
sponsible for the low C3 concentrations in type II
disease, a large contribution to the maintenance of
the low levels in some patients is apparently a re-
duced synthesis of C3 [40-42]. Reduced C3 synthesis
has also been observed in lupus nephritis [43] and
reduced C4 synthesis can be seen in patients with
hereditary angioedema [44]. It seems possible that the
reduced synthesis seen in these conditions is the result
of a negative feedback imposed on the synthetic
mechanism by the presence in the plasma of break-
down products of the complement proteins.
The origin of the C3 nephritic factor is unknown.
Presumably, its activity is not dependent on the pres-
ence of the kidneys in that nephritic factor activity
persists for at least two weeks after bilateral ne-
phrectomy [45]. Others have observed that total
complement and C3 concentrations may remain
markedly depressed for up to several years after bilat-
eral nephrectomy [10, 14, 15].
Whereas the role of complement in the pathogen-
esis of type I disease could be said to be similar or
identical to its role in lupus and acute post-
streptococcal glomerulonephritis, its role in type II
disease is obscure. There is no evidence of a direct
relationship of the C3 nephritic factor, or of alterna-
tive pathway activation, to the course of the glomer-
ulonephritis [2, 3, 46]. Highly active nephritic factor
may be present over long periods in patients whose
nephritis is quiescent or, as in patients with partial
lipodystrophy, nonexistant [22], and, conversely,
deterioration in renal function in type II disease may
occur over periods in which nephritic factor is not
demonstrable in the serum.
Approaches to therapy
The foregoing considerations suggest that, partic-
ularly in type I disease, if complex deposition in the
glomeruli could be halted, resolution of the glomeru-
lar lesion might occur. There is currently no readily
available method to demonstrate the presence of
nephritogenic complexes in the circulation. Until such
methods are available, the success of therapy designed
to reduce glomerular deposits would appear to be
best judged from serial renal biopsies. As pointed out
by others [13], the clinical characteristics of MPGN
make in many patients the renal biopsy the best
means of judging the success of therapy. However,
should therapy improve glomerular morphologic as-
pects, it is currently not possible to determine
whether the success was due to inhibition of complex
formation or inhibition of complex deposition.
Therapy designed to prevent complex deposition. Ob-
servations in experimental animals have stimulated
interest in vasoactive amines as mediators of the sub-
endothelial deposition of immune complexes. Work
initiated by Benacerraf, McCluskey and Patras in
1959 [47] and continued by Cochrane and Kniker
and Cochrane [48-50] has indicated that sub-
endothelial deposition of colloidal carbon as well as
of immune complexes in glomerular capillaries is fos-
tered by histamine. In immune complex nephritis in
rabbits, the histamine is liberated from platelets as a
result of an immune reaction which leads to the pro-
duction of a platelet-releasing factor by basophils
[51]. The disease can be ameliorated or prevented by
use of antihistamines or by platelet depletion [50, 52].
Studies by Bolton, Spargo and Lewis [53] have given
evidence that an antihistamine can also delay the
onset of autologous immune complex nephritis in
rats.
That these observations are not applicable to dis-
ease in man would be predicted from the fact that
whole blood histamine concentrations are far less
than in the rabbit [54] and there is virtually no hista-
mine in platelets [55]. Histamine in human blood is
virtually all in basophils and, under certain condi-
tions, in eosinophils [55, 56]. To date there is no
evidence for the participation of these cells in human
glomerulonephritis. In MPGN it would be intriguing
to speculate that the anaphylatoxins derived from the
involvement of C3 or C5 in the alternate pathway
reaction produced by the nephritic factor release suf-
ficient histamine to produce complex deposition. The
points against the role for this mechanism are, first,
that an anaphylatoxin inactivator is abundant in
plasma and prevents significant histamine release [57]
and, secondly, that the clinical course of MPGN does
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not correlate with either C3 or C3NeF concentrations
[2, 3, 46]. Although it is impossible to make predic-
tions from existing data, there is at present little evi-
dence that the antagonists of vasoactive amines
would be effective in the therapy of MPGN.
Therapy by prevention of complex formation. The
aim of immunosuppressive therapy, using courses of
cytotoxic agents often combined with corticosteroid,
has been, of course, to reduce the formation of im-
mune complexes. Many workers have attempted this
form of therapy but the regimens used did not appear
to alter the course of the disease [4]. The data, how-
ever, do not provide firm evidence that this approach,
or a modification of it, would be of no value. In most
instances, serial renal biopsies permitting assessment
of changes in glomerular morphology were not per-
formed. Moreover, the courses of therapy may not in
all cases have been of sufficient duration to allow
demonstration of an effect. It seems possible that
even if complex formation had been slowed or
stopped by the therapy, demonstrable improvement
in glomerular morphology would occur only after
periods measured in years. Studies by Wegmann and
Leumann [58] emphasize this point. In two patients
with nephritis due to an infected ventriculoatrial
shunt, specimens from repeat renal biopsies per-
formed 7 to 22 months after the shunt had been
removed and immune complexes presumably eradi-
cated from the circulation showed the continued pres-
ence of subendothelial deposits, mesangial hyper-
plasia and mesangial interposition.
According to preliminary data, two therapeutic
regimens may be effective in MPGN. Specimens of
serial renal biopsies from patients who for long peri-
ods had received a regimen consisting of either cyclo-
phosphamide, anticoagulants and dipyridamole [59,
60] or high-dose alternate-day prednisone [12] have
shown a reduction in the population of glomerular
deposits and partial restitution of glomerular archi-
tecture. Wider use and, ideally, prospective con-
trolled trials of these regimens will be necessary to
define their merits. Results of a controlled trial of an
alternate-day regimen employing prednisone at a
lower dose than used in the original study [12], being
conducted by the International Study of Kidney Dis-
ease in Children, are not yet available. In the case of
the triple-therapy regimen [59, 60], efforts should be
made to identify the effective constituent or con-
stituents. The constituents of both regimens might be
predicted to prevent complex formation but an effect
in halting complex deposition cannot be ruled out.
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